Treatment outcomes with oral anti‐hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population‐based cohort study
Authors' conclusion
Oral anti-hyperglycaemic therapies are effective in people with type 3c diabetes and could provide an important component of glycaemic management. PEI could identify people with type 3c requiring closer monitoring of treatment response.
Study context
- Population
- People with a pancreatic condition (acute or chronic pancreatitis, pancreatic cancer, haemochromatosis) preceding diabetes diagnosis, initiating oral glucose-lowering therapy (metformin, SU, SGLT2i, DPP-4i or TZD) without concurrent insulin; UK CPRD 2004–2020matched cohort
- Participants
- 5,917 / 1,167 / 97,227
- Exposure
- Type 3c diabetes (without or with PEI) vs matched T2D controls, on oral glucose-lowering therapy
- Type 3c without PEIn = 5,917
- Type 3c with PEIn = 1,167
- T2D controlsn = 97,227reference
- Outcome
- HbA1c reduction with oral therapies
- Follow-up
- 12 months
Methodological detailsmatched, hospital-linked UK primary care records (CPRD), 2004-2020
- Matched
- Hospital-linked UK primary care records (CPRD), 2004-2020
Main finding
As reported in the abstract
Type 3c without PEI
12.2
mean · 95% CI 12.0–12.4 · mmol/mol
Type 3c with PEI
9.4
mean · CI 8.9–10.0 · mmol/mol
Difference, mmol/mol (CI)
Between Type 3c without PEI and T2D controlssimilar mean HbA1c reduction
0.7(0.4–1.0)
Type 3c with PEIvs T2D controlslesser HbA1c reduction with Type 3c with PEI
3.5(2.9–4.1)
Observational data: associations, not effects.
Further findings
| Outcome | OR (CI) | |
|---|---|---|
| Treatment discontinuation · 6 monthsType 3c without PEIvs T2D controls | 1.08 (0.98–1.19) | |
| Treatment discontinuation · 6 monthsType 3c with PEIvs T2D controls | 2.03 (1.73–2.36) | |
| 0.512Odds ratio (log scale) |
Weight change · 12 months
- Weight change in type 3c was similar to T2D
Pancreatic conditions and drug classes
- Results largely consistent across underlying pancreatic conditions and drug classes
Original publication
Treatment outcomes with oral anti‐hyperglycaemic therapies in people with diabetes secondary to a pancreatic condition (type 3c diabetes): A population‐based cohort study. Diabetes Obes Metab. Published 6 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →